Today's Pharma Pulse
Parabilis Medicines raises $770.5M in record biotech IPO
Parabilis Medicines completed the largest biotech IPO to date, pricing 33.5 million shares at $20 each and generating $770.5 million in gross proceeds. The stock jumped 58% on its first full trading day before settling at $27.26 a week later.
Nurix Therapeutics Inks ~$3B Deal with Roche to Advance Bexobrutideg
Nurix Therapeutics and Roche announced a global collaboration to develop and co‑commercialize bexobrutideg, a BTK‑targeted protein degrader currently in Phase II/III trials for chronic lymphocytic leukemia (CLL). Nurix will receive an upfront payment of $700 million and up to $2.3 billion in milestone payments, with development costs split 40‑60 in favor of Roche. The partners will share U.S. commercialization profits and losses equally, while Roche will lead sales outside the United States. The agreement also paves the way for additional studies in other blood cancers and immune‑mediated disorders such as multiple sclerosis and chronic spontaneous urticaria.
NRIX Secures $700M Upfront, Expands Bexo Into Immunology, Neurology,
$NRIX just got $700m up front for bexo from $RHHBY. Deal includes expansion into immunology, neurology & MS
AstraZeneca Reports the P-III (I CAN) Trial Data on Ultomiris for IgA Nephropathy
AstraZeneca presented Phase III (I CAN) trial results for its complement inhibitor Ultomiris in approximately 510 adults with IgA nephropathy at risk of progression. The study showed a 46.6% reduction in 24‑hour urine protein‑to‑creatinine ratio (UPCR) versus a 5.6% rise...
Busy FDA Gives Rare Disease Sector Complementary Pathways, Unanswered Questions
The FDA has rolled out two new rare‑disease frameworks—the plausible mechanism pathway and Rare Disease Evidence Principles (RDEP)—to complement its longstanding expedited programs. Both aim to speed approval for individualized gene‑editing, RNA, and ultrarare therapies by allowing narrower evidence sets....
Post-Makary, New Rare Disease Framework Faces Fresh Uncertainty
The FDA’s plausible mechanism pathway—designed to fast‑track individualized rare‑disease therapies—faces uncertainty after the departures of Commissioner Marty Makary and CBER director Vinay Prasad. A May 4 workshop clarified that the framework is not a new approval route but a set...
Regulator Flags Gaps in Bharat Biotech's TB Vaccine Trial
India’s top drug regulator has temporarily halted Bharat Biotech’s phase‑III trial of MTBVAC, a leading tuberculosis vaccine candidate, citing data gaps and a serious adverse event in the earlier phase‑II study. The Subject Expert Committee demanded a detailed laboratory investigation...
StockWatch: Abivax Survives a Roller Coaster Week
Abivax announced that its Phase III ABTECT maintenance trial of obefazimod achieved its primary endpoint, delivering remission rates of roughly 51% versus 10% for placebo and surpassing the efficacy of existing ulcerative colitis therapies. The announcement triggered a sharp 44%...
Novo Nordisk CEO Looks Beyond Weight Loss to Longevity and Aesthetics
Novo Nordisk CEO Mike Doustdar said the company’s blockbuster GLP‑1 drugs, Ozempic and Wegovy, could be leveraged for longevity research and aesthetic medicine, not just weight loss. Recent data suggest semaglutide may protect heart, liver and kidney function independent of...
CAR-T Cells Enhanced with Navigation System to Penetrate Lymph Nodes More Efficiently
Researchers at the Max Delbrück Center engineered CAR‑T cells to overexpress the CCR7 receptor, restoring their ability to home to lymph nodes. In vitro and mouse studies showed the CCR7‑enhanced CAR‑T cells accumulated more in nodal tissue and eliminated B‑cell...
Serena Williams Endorses GLP‑1s as Mayim Bialik Warns of Side Effects, Spotlighting Pharma Debate
Serena Williams has teamed with telehealth firm Ro to tout GLP‑1 drugs for weight loss, citing a 34‑pound drop and improved mobility. Actress Mayim Bialik, meanwhile, disclosed explosive diarrhea from Ozempic, prompting Novo Nordisk to reiterate its off‑label stance. The...
Hyaluronic Acid Boosts Curcumin ZIF-8 Antitumor Power
Researchers have combined hyaluronic acid (HA) with a curcumin‑loaded ZIF‑8 metal‑organic framework to create a nanocarrier that markedly improves antitumor efficacy. The HA coating facilitates active targeting of CD44‑overexpressing cancer cells, while ZIF‑8 protects curcumin from premature degradation. In preclinical...
Pfizer and Amgen Push Monthly GLP‑1 Shots to Boost Obesity Treatment Adherence
Pfizer and Amgen announced the development of monthly GLP‑1 injections for obesity, a shift from the current weekly regimen. Early trial data show up to 12.3% average weight loss, and experts say fewer shots could improve adherence and broaden market...
Buried SSRI Failures Double Reported Efficacy Rates.
This was crazy. Burying failed SSRI trials. Published findings positive in ~100% vs 50% if they included the buried ones. Imagine reaction to bias like this psychedelic trials?! Tmk, no buried trials in psychedelic medicine. https://t.co/oRzHnk7mKu
Survodutide Delivers ~16% Weight Loss in Trials
The tide is coming in. High tide of the X-tides, that is in the new GLP-1 family of peptide drugs. Today @NEJM survodutide, a GLP-1 and glucagon dual receptor agonist (no GIP, like tirzepatide) drug that achieved ~16% body weight...
Boehringer Ingelheim’s Survodutide Phase III Trial Showed Targeted 34% Visceral and 63% Liver Fat Reduction, While Minimizing Lean Mass Loss...
Boehringer Ingelheim reported positive Phase III data for its glucagon/GLP‑1 dual agonist survodutide in two global trials. In SYNCHRONIZE‑1 (obesity without diabetes) participants lost an average of 16.6% body weight, with 34% visceral‑fat and 63% liver‑fat reductions. In SYNCHRONIZE‑MASLD (obesity with...
Zealand Pharma Announces Boehringer Ingelheim's Survodutide Phase III Trial in People Living with Obesity Showed Targeted 34% Visceral and 63%...
Zealand Pharma announced that Boehringer Ingelheim’s Phase III trials of the glucagon/GLP‑1 dual agonist survodutide (BI‑456906) met primary endpoints in both obesity (SYNCHRONIZE‑1) and metabolic‑dysfunction‑associated steatotic liver disease (SYNCHRONIZE‑MASLD). In the obesity study participants lost up to 16.6% body weight, with...
Bexorg’s Ex‑vivo Human Brain Platform Fuels Drug Discovery and Ethical Firestorm
Connecticut biotech startup Bexorg has used its BrainEx system to keep more than 700 donated human brains alive ex‑vivo for high‑throughput drug screening. The breakthrough promises faster neuro‑drug development but has ignited a fierce ethical debate over consent, consciousness and...
Biotech Race Targets $610 B Longevity Market as AI‑Driven Cell Reprogramming Gains Momentum
Beijing‑based METiS TechBio raised $269.5 million in a Hong Kong IPO and, alongside peers, is racing to capture a projected $610 billion longevity market by 2026. The push leverages AI‑driven cellular reprogramming, drawing heavyweight investors and intensifying U.S.–China competition in anti‑ageing therapeutics.
Lymphatic‑Targeted Prodrugs Boost Neuropsychiatric Oral Absorption
Loved getting these pictures. Full house w/ hundreds attending our oral presentation “Unlocking Medicines for Neuropsychiatry by Enhancing Oral Absorption Using a Lymphatic-targeting Prodrug Technology” at the American Society of Clinical Psychopharmacology annual meeting https://t.co/hylVMd1IWW
ADA: Lilly’s Weight Loss Mastery Shows Benefits in Menopause, Sleep Apnea, More
Eli Lilly showcased its obesity portfolio at the ADA meeting, highlighting the triple‑hormone agonist retatrutide and the oral GLP‑1 Foundayo. Retatrutide delivered a 28.3% body‑weight reduction (about 70 lb) after 80 weeks, slashed knee‑pain by 73%, cut moderate‑to‑severe sleep‑apnea events by 60%...
9 Mg Mazdutide for Effective Weight Loss in Chinese Adults with Obesity
A phase‑2 trial in Chinese adults with moderate to severe obesity showed that a weekly 9 mg dose of Mazdutide, a dual glucagon and GLP‑1 receptor agonist, produced statistically significant weight loss versus placebo. Presented at the 2026 American Diabetes Association...
Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes
New phase‑3 data presented at the ADA 2026 Scientific Sessions show that the apoC‑III inhibitor olezarsen reduces triglycerides by up to 65% and cuts acute pancreatitis incidence by 81% in diabetic patients with severe hypertriglyceridemia. In a parallel analysis, the...
HHS Secretary Kennedy Warns of Growing Rural‑Urban Medicare Funding Gap at Cleveland Roundtable
HHS Secretary Xavier Kennedy told a Cleveland roundtable that Medicare funding gaps between rural and urban providers are widening, jeopardizing access to advanced procedures. He linked the disparity to broader federal enforcement actions, including a $3 million Medicaid fraud funding cut...
Harvard Oncologist Delivers 'Grand Slam' With Daraxonrasib Data at ASCO
Harvard oncologist Brian Wolpin unveiled data showing daraxonrasib almost doubled median overall survival in a 500‑patient trial of advanced pancreatic cancer at the ASCO meeting. The result, hailed as a "grand slam" and a "game changer," could reshape treatment standards...
Teva's AUSTEDO Shows Quality‑of‑Life Gains in Huntington's Chorea Study
Teva Pharmaceuticals released data from a decentralized, real‑world study showing that its AUSTEDO and AUSTEDO XR therapies improved chorea‑related quality of life for 60‑71% of Huntington's disease patients. The findings highlight a new market opportunity in a rare‑disease space where...
Triple-Action Diabetes Jab Shown to Reduce Blood Sugar and Body Weight
Eli Lilly’s triple‑action weekly injection retatrutide delivered dramatic improvements in a phase 3 trial of 930 type 2 diabetes patients. Over 40 weeks, participants saw HbA1c reductions of 1.7‑1.9 percentage points and lost 11.5‑15.3% of body weight, roughly four times the placebo effect. The...
Rapamycin (Sirolimus) Clinical Evidence Guide: 2026 Medical Standards
The 2026 Clinical Evidence Guide positions rapamycin as the most validated geroprotector, recommending a weekly 3‑8 mg pulse to trigger autophagy while sparing mTORC2 and avoiding insulin resistance. Metformin remains a cornerstone for glucose control and modest longevity benefits, yet its...
Cloudbreak Pharma Completes Phase 3 Endpoint Visit for CBT-001 Eye Drop
Cloudbreak Pharma Inc. announced that the last participant in its Phase 3 study of CBT-001, an eye‑drop multi‑kinase inhibitor for pterygium, finished the 12‑month endpoint visit. The trial closure moves the company toward regulatory submission for a condition affecting up...
First Leishmaniasis Vaccine Enters Phase One Trial as Disease Spreads to US
A CRISPR‑engineered live vaccine against cutaneous leishmaniasis has received FDA investigational new drug approval, launching a phase‑1 safety trial in Kenya, Brazil and possibly Cincinnati. The vaccine deletes the centrin gene from Leishmania major, creating an attenuated parasite that provokes...
Common Arthritis Drugs Reduce Systemic Sjögren's Disease Activity in 24 Weeks
A phase‑2b trial (RepurpSS‑II) in the Netherlands found that a daily oral combo of leflunomide and hydroxychloroquine reduced systemic Sjögren's disease activity by more than four points on the ESSDAI scale after 24 weeks, compared with placebo. The study enrolled...
Tired of Nausea or Taking a GLP-1 Pill Every Day? These Experimental Drug...
Retatrutide, Eli Lilly’s once‑weekly triple‑agonist, delivered up to 28% body‑weight reduction in Phase 3 trials, outperforming existing GLP‑1 therapies. The drug also improved obesity‑related conditions such as sleep apnea, signaling broader health benefits. Wall Street expects a U.S. launch in 2027, contingent...
FDA Week Highlights: Philips AI Ultrasound Clears, KMDA Approved, Multiple Deals and Halts
Philips (PHG) secured FDA 510(k) clearance for its AI‑enhanced Elevate Plus ultrasound platform, while biotech firm KMDA also received an FDA nod. The week saw Fulcrum Therapeutics (FULC) pause a pivotal study, RMD close a Noctrix acquisition, and Novartis (NVS)...
Serena Williams' GLP‑1 Endorsement Fuels Surge in Peptide Use Among Elite Athletes
Tennis legend Serena Williams appeared in a Super Bowl commercial for telehealth firm Ro, praising GLP‑1 drugs for weight loss and mobility. Her endorsement has amplified a growing trend among elite athletes and affluent patients to use injectable peptides for...
Popular Weight Loss and Diabetes Drugs Show No Biological Link to Mental Illness
A combined genetic and clinical study found no evidence that glucagon‑like peptide‑1 (GLP‑1) receptor agonists, the drugs driving the recent obesity‑diabetes treatment boom, increase the risk of depression, anxiety, or suicide. Researchers used Mendelian randomization with data from FinnGen and...
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide
Pfizer reported robust Phase 2b data for berobenatide (PF’3944), a potential first‑in‑class monthly GLP‑1 receptor agonist peptide. In the VESPER‑1 extension, participants on 2.4 mg weekly dosing lost 15.9% of body weight after 32 weeks with no plateau. Weekly dosing also cut HbA1c...
Hair-Size Microrobots Combine Three Cancer-Fighting Functions in Preclinical Animal Tests
Michigan State University researchers have created a hair‑size 3D‑printed microrobot, TriMag, that integrates magnetic navigation, real‑time imaging, and hyperthermia heating to destroy tumors. In preclinical animal tests, the biodegradable device could be steered through tissue, tracked with magnetic particle imaging,...
Gilead and Lakefront Close $1.67 B Deal for Ouro Medicines' T‑Cell Engager Platform
Gilead Sciences and private‑equity‑backed Lakefront Biotherapeutics completed a $1.675 billion acquisition of Ouro Medicines, securing a pipeline of T‑cell engager therapies. The transaction splits upfront and milestone payments between the two buyers and gives Lakefront operational control of Ouro’s assets.
InnoCare Reports Positive Phase 2b Data for Orelabrutinib in Lupus
InnoCare Pharma Limited announced that its BTK inhibitor Orelabrutinib met the primary endpoint in a randomized Phase 2b trial of 187 patients with moderate to severe systemic lupus erythematosus, data shown at the 2026 EULAR Congress. The result marks a...
Arizona’s $5 Million Psilocybin Trial Advances with First‑Responder Cohort
Dr. Sue Sisley’s Scottsdale Research Institute has completed dosing the first 24 participants in Arizona’s $5 million state‑backed trial of whole‑mushroom psilocybin for PTSD. The study, the nation’s first to use intact mushrooms in a regulated clinical setting, will finish its initial...
Oxford AI-Designed Vaccine Enters First Human Trials for Crimean-Congo Hemorrhagic Fever
Researchers at the University of Oxford, in partnership with Basecamp Research, have begun the first human clinical trial of a vaccine designed entirely with artificial intelligence. Targeting Crimean-Congo hemorrhagic fever, the trial aims to prove safety and immune response, showcasing...
How FDA’s June 2026 Draft Guidance Lets Genome Editing Sponsors Reuse CMC, Nonclinical, Bioinformatics, and Clinical Data Across Programs, and...
The FDA’s Center for Biologics released a June 2026 draft guidance that clarifies when genome‑editing sponsors can reuse chemistry, manufacturing, controls (CMC), non‑clinical, bioinformatics and clinical data from earlier programs. The non‑binding, comment‑only document, a PDUFA VII deliverable, categorises prior knowledge...
GLP‑1 Drugs Show 28% Weight Loss, Cut Breast Cancer Risk, and Quiet Cravings
Three recent studies – a Nature paper on brain circuitry, Eli Lilly’s TRIUMPH‑1 Phase 3 trial, and a June 2026 cancer‑outcome analysis – show GLP‑1 drugs not only suppress appetite but also dampen reward‑driven eating, produce up to 28% body‑weight loss, and...
BioCardia Shares Jump 48% After FDA Backs CardiAMP Approval Pathway
BioCardia, Inc. saw its Nasdaq‑listed shares climb 48.13% to $1.36 after the U.S. Food and Drug Administration confirmed that data from the Phase 3 CardiAMP Heart Failure II trial could form the basis of a Premarket Approval (PMA) filing. The regulatory nod...
OrsoBio to Present Preclinical and Clinical Data From Its Mitochondrial Protonophore Portfolio at the American Diabetes Association’s 2026 Scientific Sessions
OrsoBio will unveil Phase 2a results showing its oral mitochondrial protonophore TLC‑6740 adds a 4.5% absolute weight‑loss advantage when paired with tirzepatide, while also improving insulin sensitivity, liver health and body composition without new safety signals. The company will also present...
Kura Oncology Reports 67% Response Rate for Darlifarnib Combo in Pancreatic Cancer at ASCO
Kura Oncology announced a 67% confirmed objective response rate for its darlifarnib and adagrasib combination in KRAS G12C‑mutated pancreatic ductal adenocarcinoma, based on Phase 1a data presented at ASCO 2026. The early signal, derived from 26 evaluable patients, could reshape...
ADA: Obesity Partners Zealand and Roche Aim for Weight Loss ‘Sweet Spot’ with Amylin Agonist
Roche and its partner Zealand reported that their amylin analog petrelintide produced a 9% weight reduction after 42 weeks in the Phase 2 ZUPREME‑1 trial, falling short of analyst expectations for 12% loss and behind Lilly’s eloralintide. The companies argue that...
Correlation Between Prognostic Nutritional Index and Oral Mucositis in Patients with Lung Adenocarcinoma Treated with Almonertinib: A Multicenter Prospective Study
A multicenter prospective study of 537 Chinese lung adenocarcinoma patients treated with the third‑generation EGFR‑TKI almonertinib found that low baseline prognostic nutritional index (PNI) significantly increased the risk of oral mucositis (OM). Each one‑unit rise in PNI reduced OM odds...
FDA Encourages Reintroduction of Bovine-Sourced Heparin
The FDA announced it will actively encourage the reintroduction of bovine‑sourced heparin into the U.S. market, inviting manufacturers to engage through the pre‑IND process. Historically, bovine lung heparin was used safely for six decades before being withdrawn in the late...
H. Lundbeck A/S (HLBBF) Discusses PROCEED Trial Results and Data Presented at AHS on Bokunebart for Headache Treatment Transcript
Lundbeck presented Phase 3 PROCEED trial data for its migraine therapy bokunebart (formerly Lu AG09222) at the American Headache Society meeting. The study met its primary endpoint, showing a roughly 45% reduction in monthly migraine days versus placebo, and demonstrated a...
MAIA Therapeutics Targets 100 Patients in Phase 3 NSCLC Trial of Ateganosine
MAIA Therapeutics announced that its Phase 3 THIO-104 trial of ateganosine in third‑line non‑small cell lung cancer has dosed 29 patients across 34 sites and will aim for 100 enrollments by year‑end. The FDA granted Fast Track designation, positioning the...